Peringatan Keamanan

Data regarding ipilumumab overdose is not readily available.L12126 However, the most common adverse reactions to ipilumumab are fatigue, diarrhea, pruritus, rash, and colitis.L12126

Ipilimumab

DB06186

biotech approved

Deskripsi

Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4).L12126 Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.A35065,A35080,L12126 Ipilimumab was developed by Bristol-Myers Squibb and Medarex.L12126

Ipilimumab was granted FDA approval on 25 March 2011.L12126

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Ipilimumab has a half life of 14.7 days.[A35118]
Volume Distribusi The volume of distribution at steady-state of ipilimumab is 7.21L.[A35118]
Klirens (Clearance) Ipilimumab has a clearance of 15.3 mL/hr.[A35118] Systemic clearance increases proportionally with body weight.[L12642]

Absorpsi

Cmax was 65.8µg/mL for 2-6 year olds, 70.1µg/mL for 6-<12 year olds, and 73.3µg/mL in patients 12 years and older.L12126 Data regarding the AUC and Tmax of ipilumumab are not readily available.A35118,L12126

Metabolisme

The metabolism of ipilimumab does not involve the cytochrome P450 enzyme system.L12126,L12642 Because ipilimumab is a protein, it is expected to be degraded into small peptides and amino acids by proteolytic enzymes.A35122

Rute Eliminasi

Data regarding the route of elimination of ipilimumab is not readily available.L12126

Interaksi Obat

1123 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Ipilimumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Ipilimumab.
Estrone Estrone may increase the thrombogenic activities of Ipilimumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Ipilimumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Ipilimumab.
Mestranol Mestranol may increase the thrombogenic activities of Ipilimumab.
Estriol Estriol may increase the thrombogenic activities of Ipilimumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Ipilimumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Ipilimumab.
Tibolone Tibolone may increase the thrombogenic activities of Ipilimumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Ipilimumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Ipilimumab.
Zeranol Zeranol may increase the thrombogenic activities of Ipilimumab.
Equol Equol may increase the thrombogenic activities of Ipilimumab.
Promestriene Promestriene may increase the thrombogenic activities of Ipilimumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Ipilimumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Ipilimumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Ipilimumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Ipilimumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Ipilimumab.
Formononetin Formononetin may increase the thrombogenic activities of Ipilimumab.
Estetrol Estetrol may increase the thrombogenic activities of Ipilimumab.
Vemurafenib Ipilimumab may increase the hepatotoxic activities of Vemurafenib.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ipilimumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ipilimumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ipilimumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Ipilimumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Ipilimumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ipilimumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ipilimumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Ipilimumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ipilimumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Ipilimumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Ipilimumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Ipilimumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ipilimumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ipilimumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ipilimumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ipilimumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Ipilimumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ipilimumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Ipilimumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Ipilimumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Ipilimumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ipilimumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ipilimumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Ipilimumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Ipilimumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Ipilimumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Ipilimumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Ipilimumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Ipilimumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Ipilimumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Ipilimumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Ipilimumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Ipilimumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Ipilimumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Ipilimumab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Ipilimumab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Ipilimumab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Ipilimumab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Ipilimumab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Ipilimumab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Ipilimumab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Ipilimumab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Ipilimumab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Ipilimumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Ipilimumab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Ipilimumab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Ipilimumab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Ipilimumab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Ipilimumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Ipilimumab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Ipilimumab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Ipilimumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Ipilimumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Ipilimumab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Ipilimumab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Ipilimumab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ipilimumab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Ipilimumab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Ipilimumab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Ipilimumab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Ipilimumab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Ipilimumab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Ipilimumab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Ipilimumab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Ipilimumab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ipilimumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Ipilimumab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Ipilimumab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Ipilimumab.
Canakinumab The risk or severity of adverse effects can be increased when Canakinumab is combined with Ipilimumab.
Nimotuzumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Nimotuzumab.
Clenoliximab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Clenoliximab.
Tocilizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Tocilizumab.
BIIB015 The risk or severity of adverse effects can be increased when Ipilimumab is combined with BIIB015.
Sonepcizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Sonepcizumab.
Motavizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Motavizumab.
Elotuzumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Elotuzumab.

Target Protein

Cytotoxic T-lymphocyte protein 4 CTLA4

Referensi & Sumber

Artikel (PubMed)
  • PMID: 25964307
    Johnson DB, Peng C, Abramson RG, Ye F, Zhao S, Wolchok JD, Sosman JA, Carvajal RD, Ariyan CE: Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. Oncologist. 2015 Jun;20(6):648-52. doi: 10.1634/theoncologist.2014-0468. Epub 2015 May 11.
  • PMID: 21294471
    Thumar JR, Kluger HM: Ipilimumab: a promising immunotherapy for melanoma. Oncology (Williston Park). 2010 Dec;24(14):1280-8.
  • PMID: 23047236
    Trinh VA, Hagen B: Ipilimumab for advanced melanoma: a pharmacologic perspective. J Oncol Pharm Pract. 2013 Sep;19(3):195-201. doi: 10.1177/1078155212459100. Epub 2012 Oct 9.
  • PMID: 23066344
    Fellner C: Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P T. 2012 Sep;37(9):503-30.

Contoh Produk & Brand

Produk: 7 • International brands: 1
Produk
  • Yervoy
    Injection • 5 mg/1mL • Intravenous • US
  • Yervoy
    Injection • 5 mg/1mL • Intravenous • US
  • Yervoy
    Injection • 5 mg/1mL • Intravenous • US • Approved
  • Yervoy
    Injection • 5 mg/1mL • Intravenous • US • Approved
  • Yervoy
    Solution • 5 mg / mL • Intravenous • Canada • Approved
  • Yervoy
    Injection, solution, concentrate • 5 mg/ml • Intravenous • EU • Approved
  • Yervoy
    Injection, solution, concentrate • 5 mg/ml • Intravenous • EU • Approved
International Brands
  • Yervoy

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul